PURETECH HEALTH, PLC

REGISTERED NO 09582467

UNAUDITED INTERIM COMPANY FINANCIAL STATEMENTS

FOR THE PERIOD FROM JANUARY 1, 2022 THROUGH MAY 6, 2022

PREPARED FOR THE PURPOSE OF SECTION 838 COMPANIES ACT 2006

PURETECH HEALTH, PLC

REGISTERED NO 09582467

UNAUDITED INTERIM PARENT COMPANY FINANCIAL STATEMENTS FOR THE PERIOD FROM JANUARY 1, 2022 THROUGH MAY 6, 2022

Income Statement	**Period From January 1, 2022 through May 6, 2022**
	$000s
Dividend Income	65,000
Administrative Expenses	(22)
Profit Before tax	64,978
Income Tax Expense	-
Profit for the Period	64,978

PURETECH HEALTH, PLC

REGISTERED NO 09582467

UNAUDITED INTERIM PARENT COMPANY FINANCIAL STATEMENTS FOR THE PERIOD FROM JANUARY 1, 2022 THROUGH MAY 6, 2022

Balance sheet

	Note	**6 May 2022** $000s
Assets		
Non-current Assets		
Investment in Subsidiary		148,086
Intercompany Long-Term Receivable		297,909
Total non-current Assets		445,995
Cash		65,000
Total current assets		65,000
Total assets		510,995
Equity and liabilities		
Equity		
Share capital		5,446
Share premium		289,301
Merger reserve		138,506
Other reserve		7,730
Retained Earnings	3	50,956
Total equity		491,939
Current liabilities		
Trade and other payables		1,872
Intercompany payables		17,185
Total current liabilities		19,056
Total equity and liabilities		510,995

The Board considered the interim financial statements of the Company for the period ended May 6, 2022, which were prepared under section 838 of the Companies Act 2006 (the "Act") for the purposes of confirming that the Company has sufficient distributable profits to support the proposed return of capital.

The Board are of the opinion that the accounts have been 'properly prepared' within the meaning of section 838 of the Act, subject only to matters which are not material for determining (by reference to items mentioned in section 836(1) of the Act which are included in the accounts) whether the proposed distribution would contravene the relevant requirements of the Act.

These Company unaudited interim financial statements were approved by the Board of Directors on May 6, 2022.

Approved by the board of directors and signed on their behalf by:

Daphne Zohar
Director
May 6, 2022

The accompanying Notes are an integral part of these financial statements.

PURETECH HEALTH, PLC

REGISTERED NO 09582467

UNAUDITED INTERIM PARENT COMPANY FINANCIAL STATEMENTS FOR THE PERIOD FROM JANUARY 1, 2022 THROUGH MAY 6, 2022

Statement of changes in Equity

	Share Capital						
	Shares	Amount $000s	Share premium	Merger reserve $000s	Other reserve $000s	Retained earnings (Accumulated deficit) $000s	Total parent equity $000s
Balance 31 December 2021	**287,796,585**	**5,444**	**289,303**	**138,506**	**7,730**	**(14,022)**	**426,961**
Total comprehensive loss for the period							
Exercise of Share Based Awards	**104,819**	**2**	**(2)**				**0**
Net Income						**64,978**	64,978
Balance 6 May 2022	**287,901,404**	**5,446**	**289,301**	**138,506**	**7,730**	**50,956**	**491,938**

Notes to the Unaudited Company Interim Financial Statements

1. General Information

   PureTech Health PLC (the Company) is a public limited company incorporated and domiciled in the United Kingdom under the Companies Act 2006 (Registration number 09582467). The address of the registered office is 8th Floor, 20 Farringdon Street, London EC4A 4AB United Kingdom.

2. Basis of preparation

   These interim accounts have been prepared for the purposes of Sections 836 and 838 of the Companies Act 2006 (the "Act"). They are abridged and unaudited. These interim accounts have been prepared for the purposes of confirming that the Company has sufficient distributable profits to support a planned return of capital to shareholders.

   These financial statements contain information about PureTech Health plc solely as an individual company and do not contain consolidated financial information for the group of companies of which PureTech Health plc is the ultimate parent company. These interim accounts have been prepared on the basis of the same recognition and measurement basis as adopted by the company in preparing the company's financial statements included within the annual report for the year ended 31 December 2021, except for the matter described below.

   The Board are of the opinion that the interim accounts have been properly prepared within the meaning of Section 838 of the Act, subject only to matters which are not material for determining (by reference to items mentioned in Section 836(1) of the Act which are included in the accounts) whether the proposed distribution is permitted by section 830 and 831 of the Act. The directors have chosen not to present comparative figures for the period and the note disclosures that would normally form part of a set of complete financial statements.

   These interim accounts do not contain the impact of share-based compensation awards granted in subsidiaries to their employees and consultants to be settled in the Company's equity instruments. Specifically, these accounts do not contain the increase to the investment in subsidiaries with a corresponding increase in Other Reserve for the amount of compensation to be recognized for the period from January 1, 2022 to May 6, 2022. This matter does not affect the profits available for distribution or Retained Earnings presented in these accounts.

   The interim financial statements do not constitute statutory accounts within the meaning of sections 434(3) of the 2006 Act. Statutory accounts for the year to 31 December 2021 were published in PureTech Health plc's Annual Report and delivered to the Registrar of Companies in England and Wales. The auditor's report on those accounts was unqualified, did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying the report, and did not contain any statement under sections 498(2) or (3) of the 2006

Act. No statutory accounts have been delivered to the Registrar of Companies in England and Wales in respect of the period covered by these interim accounts.

3. Retained Earnings

The Company's profits being used for this distribution arose from receipt, since 31 December 2021, of $65.0 million of cash settled distributions, from the US subsidiary PureTech Health LLC.

The Company has considered the profits available for distribution to shareholders. At 31 December 2021, the company had an accumulated deficit of $14.0million. After including the $65.0 million distribution and the 1st quarter net operating loss of $22.0 thousand, the Company has $50.9 million profits available for distribution. The Company's retained earnings do not contain any unrealised profits.